A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment

Cancer Journal (United States)

Volumn 21, Issue 4, 2015, Pages 274-283

  Kerbel, Robert S ^a,b  

^a Canada   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

antiangiogenic drugs; experimental therapeutic investigations; metronomic low dose chemotherapy; spontaneous metastatic disease

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY DC101; OXALIPLATIN; PACLITAXEL; PAZOPANIB; RAMUCIRUMAB; SUNITINIB; TOPOTECAN; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ADVANCED CANCER; ANGIOGENESIS; BRAIN METASTASIS; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CARCINOMA; DISTANT METASTASIS; EARLY CANCER; HUMAN; METASTASIS; METRONOMIC CHEMOTHERAPY; MICROMETASTASIS; MONOTHERAPY; NONHUMAN; OVARY CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER TRANSPLANTATION; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; FEMALE; KIDNEY NEOPLASMS; MELANOMA; METRONOMIC DRUG ADMINISTRATION; MOUSE; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PATHOLOGY; PRECLINICAL STUDY; TUMOR CELL LINE; VASCULARIZATION;

ADMINISTRATION, METRONOMIC; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MELANOMA; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84938560568     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000134     Document Type: Review

References (91)

1. Francia G, Cruz-Munoz W, Man S, et al. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer. 2011;11:135-141.
2. Kamb A. What's wrong with our cancer models? Nat Rev Drug Discov. 2005;4:161-165.
3. Sharpless NE, DePinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov. 2006; 5:741-754.
4. Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9: 338-350.
5. Francia G, Kerbel RS. Raising the bar for cancer therapy models. Nat Biotechnol. 2010;28:561-562.
6. Munoz R, Man S, Shaked Y, et al. Highly efficacious non-toxic treatment for advanced metastatic breast cancer using combinationUFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006;66:3386-3391.
7. Cruz-Munoz W, Man S, Xu P, et al. Development of a preclinical model of spontaneous human melanoma CNS metastasis. Cancer Res. 2008;68: 4500-4505.
8. Hackl C,Man S, Francia G, et al. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut. 2013;62:259-271.
9. Jedeszko C, Paez-Ribes M, Di Desidero T, et al. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Sci Transl Med. 2015;7:282ra50.
10. Ebos JML, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232-239.
11. Hashimoto K, Man S, Xu P, et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther. 2010;9:996-1006
12. Francia G, Emmenegger U, Lee CR, et al. Long term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-hCGchoriogonadotropin secreting tumor cell lines. Mol Cancer Ther. 2008;7:3452-3459.
13. Moriyama EH, Niedre MJ, JarviMT, et al. The influence of hypoxia on bioluminescence in luciferase-transfected gliosarcoma tumor cells in vitro. Photochem Photobiol Sci. 2008;7:675-680.
14. Kubota T. Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation. J Cell Biochem. 1994; 56:4-8.
15. Morikawa K, Walker SM, Jessup JM, et al. In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res. 1988;48:1943-1948.
16. Meyer JS. Cell kinetic measurements of human tumors. Hum Pathol. 1982; 13:874-877.
17. Tang TC, Man S, Lee CR, et al. Impact of UFT/cyclophosphamide metronomic chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia. 2010;12:264-274.
18. Tang TC, Man S,Xu P, et al. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia. 2010;12:928-940.
19. Guerin E,Man S, Xu P, et al. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res. 2013;73:2743-2748.
20. Singh M, Lima A, Molina R, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol. 2010;28:585-593.
21. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003;2:1011-1021.
22. Mackey JR, Kerbel RS, Gelmon KA, et al. Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treat Rev. 2012;38:673-688.
23. Bergh J, Greil R, Voytko N, et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol. 2011;28:LBA 1010.
24. Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer. 2011;11:82-92.
25. Crown JP, Dieras V, Staroslawska E, et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol. 2013;31:2870-2878.
26. Ratner M. Fearful of Avastin's fate, Genentech asks for unusual hearing. Nat Med. 2011;17:233.
27. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357: 2666-2676.
28. Mackey JR, Ramos-VazquezM, Lipatov O, et al. Primary results of ROSE/ TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J ClinOncol. 2015;33:141-148.
29. Burstein HJ. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol. 2011;29:1232-1235.
30. Pivot X, Schneeweiss A, Verma S, et al. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer. 2011;47:2387-2395.
31. Ohtsu A, ShahMA, Van CE, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, doubleblind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968-3976.
32. Wilke H, Muro K, Van CE, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a doubleblind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224-1235.
33. Sasako M. Ramucirumab: second-line therapy for gastric cancer. Lancet Oncol. 2014;15:1182-1184.
34. Donnem T, Hu J, Ferguson M, et al. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med. 2013;2:427-436.
35. Pezzella F, Di BA, Andreola S, et al. Angiogenesis in primary lung cancer and lung secondaries. Eur J Cancer. 1996;32A:2494-2500.
36. Pezzella F, Pastorino U, Tagliabue E, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol. 1997;151:1417-1423.
37. Kerbel RS, Kamen BA. Antiangiogenic basis of low-dose metronomic chemotherapy. Nature Rev Cancer. 2004;4:423-436.
38. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis inmice. J Clin Invest. 2000;105:1045-1047.
39. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-1886.
40. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15-R24.
41. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455-465.
42. Kerbel RS. Development and evolution of the concept of metronomic chemotherapy: a personal perspective. In: Metronomic Chemotherapy: Pharmacology and Clinical Applications. Springer; 2014:3-22.
43. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and lowdose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63:4342-4346.
44. Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: blocking rebound by the tumor vasculature after chemotherapy. Cancer Res. 2007; 67:7055-7058.
45. HaradaM. Effects of metronomic chemotherapy on immunity. In: Bocci G, Francia G, eds. Metronomic Chemotherapy: Pharmacology and Clinical Applications. Springer; 2015:39-52.
46. Rapisarda A, Zalek J, HollingsheadM, et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 2004;64:6845-6848.
47. Onnis B, Rapisarda A,Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med. 2009;13:2780-2786.
48. Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol. 2009;16: 7-15.
49. Pham E, Birrer MJ, Eliasof S, et al. Translational impact of nanoparticledrug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res. 2015;21:808-818.
50. Folkins C, Man S, Shaked Y, et al. Anti-cancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stemlike cell fraction in glioma xenograft tumors. Cancer Res. 2007;67: 3560-3564.
51. Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated withmaximum antiangiogenic activity. Blood. 2005;106:3058-3061.
52. Osterlund P, Soveri LM, Isoniemi H, et al. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumabcontaining chemotherapy. Br J Cancer. 2011;104:599-604.
53. Pietras K, Hanahan D. A multitargeted, metronomic, and maximumtolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005;23:939-952.
54. Simkens LHJ, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer, the phase 3 CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). Lancet. 2015;385:1843-1852.
55. Kerbel RS, Grothey A. Rationale for metronomic chemotherapy in phase III trials. Nat Rev Clin Oncol. 2015;12:313-314.
56. Colleoni M, Gray KP, Gelber SI, et al. Low-dose oral cyclophosphamidemethotrexate maintenance (CMM) for receptor-negative early breast cancer (BC). J Clin Oncol. 2015;33:Abstr 1002.
57. de Gramont A, Van CE, Schmoll HJ, et al. Bevacizumab plus oxaliplatinbased chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225-1233.
58. CameronD, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14:933-942.
59. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11-16.
60. Allegra CJ, Yothers G, O'ConnellMJ, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol. 2013;31:359-364.
61. Ebos JML, Kerbel RS. Impact of antiangiogenic therapy on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8:210-221.
62. Schneider BP, Sledge GW Jr. Anti-VEGF therapy as adjuvant therapy: clouds on the horizon? Breast Cancer Res. 2009;11:303.
63. Blagoev KB, Wilkerson J, Stein WD, et al. Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Rep. 2013;3:277-281.
64. Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol. 2011;29:83-88.
65. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-231.
66. Conley SJ, Gheordunescu E, Kakarala P, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A. 2012;109:2784-2789.
67. Sennino B, Ishiguro-Oonuma T,WeiY, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012;2:270-287.
68. Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70: 10090-10100.
69. Grepin R, Guyot M, Jacquin M, et al. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines. Oncogene. 2012;31:1683-1694.
70. LuKV, Chang JP, Parachoniak CA, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 2012;22:21-35.
71. Maione F, Capano S, Regano D, et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest. 2012;122:1832-1848.
72. Takeda T, Okuyama H, Nishizawa Y, et al. Hypoxia inducible factor-1alpha is necessary for invasive phenotype in VEGF-deleted islet cell tumors. Sci Rep. 2012;2:494.
73. Welti JC, Powles T, Foo S, et al. Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis. 2012;15:623-641.
74. Zhang W, Sun HC, Wang WQ, et al. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. Gastroenterology. 2012;143: 1641-1649.
75. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3:347-361.
76. Singh M, Couto SS, Forrest WF, et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol. 2012;227:417-430.
77. RovidaA, CastiglioniV, DecioA, et al. Chemotherapy counteractsmetastatic dissemination induced by antiangiogenic treatment in mice. Mol Cancer Ther. 2013;12:2237-2247.
78. Paez-Ribes M, Man S, Xu P, et al. Potential pro-invasive or metastatic effects of preclinical antiangiogenic therapy are prevented by concurrent chemotherapy. Clin Cancer Res. 2015.
79. Rapisarda A, Hollingshead M, Uranchimeg B, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. 2009;8:1867-1877.
80. Cruz-MunozW, Kerbel RS. Preclinical approaches to study the biology and treatment of brain metastases. Semin Cancer Biol. 2011;21:123-130.
81. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;15:1648-1655.
82. Steeg PS, Anderson RL, Bar-Eli M, et al. Preclinical drug developmentmust consider the impact on metastasis. Clin Cancer Res. 2009;15:4529-4530.
83. Cruz-MunozW, Jaramillo ML, Man S, et al. Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Res. 2012;72:4909-4919.
84. Kim SW, Choi HJ, Lee HJ, et al. Role of the endothelin axis in astrocyteand endothelial cell-mediated chemoprotection of cancer cells. Neuro Oncol. 2014;16:1585-1598.
85. Khadka A, Singh Brashier DB, Tejus A, et al.Macitentan: an important addition to the treatment of pulmonary arterial hypertension. J Pharmacol Pharmacother. 2015;6:53-57.
86. Bankert RB, Balu-Iyer SV, Odunsi K, et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One. 2011;6:e24420.
87. Doornebal CW, Klarenbeek S, Braumuller TM, et al. A preclinical mouse model of invasive lobular breast cancer metastasis. Cancer Res. 2013;73: 353-363.
88. Rampetsreiter P, Casanova E, Eferi R. Genetically modified mouse models of cancer invasion andmetastasis. Drug Discov Today DisModels. 2011;8:67-74.
89. Saxena M, Christofori G. Rebuilding cancer metastasis in the mouse. Mol Oncol. 2013;7:283-296.
90. Cho H, Herzka T, Zheng W, et al. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Ptenmutant metastasis. Cancer Discov. 2014;4:318-333.
91. Adelaiye-Ogala RM, Shen L, Chintala S, et al. Antitumor and antimetastatic effect of sunitinib in a patient derived metastatic clear cell renal cell carcinoma xenograft model. Presented at the AACR 2015 Annual Meeting 2015. Abst. no. 4132.